Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Most Deregulations Proposed by Korosho Approved
October 28, 2002
- Asahi Kasei to Pursue "Selection and Concentration" Policy
October 28, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 28, 2002
- Sumitomo Chemical, Takeda to Establish New Agrochemical JV
October 28, 2002
- Ingredients in Ashitaba Effective for Osteoporosis: Takara Bio
October 28, 2002
- Suzuken Ties Up with Ando Chemical Works
October 28, 2002
- Cloned Cow for Organ Transplantation Produced by TWMU, ZEN-NOH
October 28, 2002
- WEBSITE NEWS
October 28, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 28, 2002
- BUSINESS NEWS IN BRIEF
October 28, 2002
- Matsumotokiyoshi Ties Up with Koyo Yakuhin
October 28, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
October 28, 2002
- Interim Report Drafted on Promotion of OTC Drugs
October 28, 2002
- Korosho to Take Measures to Improve Quality of Medical Services
October 28, 2002
- MEDICAL DEVICE NEWS IN BRIEF
October 28, 2002
- Review Fees to Be Hiked in April 2004
October 28, 2002
- DIAGNOSTIC NEWS IN BRIEF
October 28, 2002
- Council Recommends Strategic Approaches toward IP
October 28, 2002
- WORLD NEWS IN BRIEF
October 28, 2002
- 3 Active Ingredients Including Flunase Nasal Solution Approved
October 28, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…